The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer.
“There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS,” said NICE.
The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment.
Helen Knight, director of medicines evaluation at NICE, said: “Today’s draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.
“It also means NICE has made positive recommendations in all 18 of its appraisals of breast cancer medicines since March 2018. These are all now available for clinicians to use in the treatment of thousands of NHS patients and demonstrate how NICE works successfully at the interface of health and care and the life sciences industry to enable early access to innovation.”
